Orphan Drug Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Orphan Drug stocks.

Orphan Drug Stocks Recent News

Date Stock Title
May 3 FOLD ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
May 2 GMAB Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript
May 2 GMAB Genmab A/S 2024 Q1 - Results - Earnings Call Presentation
May 2 GMAB Genmab reports Q1 results
May 2 GMAB Genmab Announces Financial Results for the First Quarter of 2024
May 1 GMAB Genmab Q1 2024 Earnings Preview
May 1 GMAB Genmab: A Complicated Tale
May 1 CYTK Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
May 1 FOLD Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
May 1 GMAB Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
May 1 FOLD Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
Apr 30 GMAB Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
Apr 30 GMAB Pfizer, Genmab cervical cancer therapy wins full FDA approval
Apr 29 GMAB FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
Apr 29 GMAB TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Apr 29 CYTK Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Apr 29 BIVI BioVie awarded up to $13.1M in funding from U.S. DOD for long COVID treatment
Apr 29 BIVI BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
Apr 27 GYRE Public companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last week
Apr 26 CYTK Cytokinetics names Sung Lee as CFO
Orphan Drug

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy in many countries and has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.In the U.S. and the EU, it is easier to gain marketing approval for an orphan drug. There may be other financial incentives, such as an extended period of exclusivity, during which the producer has sole rights to market the drug. All are intended to encourage development of drugs which would otherwise lack sufficient profit motive to attract corporate research budgets and personnel.

Browse All Tags